Entry |
|
Name |
Iratumumab (USAN) |
Efficacy |
Antineoplastic, Anti-CD30 antibody |
Comment |
Monoclonal antibody
Treatment of relapsed or refractory CD30 positive lymphoma including Hodgkin's disease
|
Target |
|
Pathway |
hsa04060 | Cytokine-cytokine receptor interaction |
|
Brite |
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokine receptors
Tumor necrosis factor receptors
TNFRSF8 (CD30)
D04612 Iratumumab (USAN)
|
Other DBs |
|
LinkDB |
|